Inner Mongolia Keran Bio-Tech Co., Ltd – Trademark Portfolio

Entity Type: 99

Inner Mongolia Keran Bio-Tech Co., Ltd has 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO). Filings span 3 Nice Classification classes, led by Class 35 (Advertising & Business) and Class 5 (Pharmaceuticals). This trademark owner is based in Inner Mongolia.

Shangjing Jizhong Industrial Park,

Balinzuoqi, Chifeng City,

Inner Mongolia 024000 , CN

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

IMNKERAN
IMNKERAN
Abandoned 2023
IMNKERAN
IMNKERAN
Abandoned 2023
IMNKERAN
IMNKERAN
Abandoned 2023

Trademark Classifications

Inner Mongolia Keran Bio-Tech Co., Ltd's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

35
Advertising & Business (1 filing)

Advertising; business management; business administration; office functions

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

30
Staple Foods (1 filing)

Coffee, tea, cocoa and artificial coffee; rice; tapioca and sago; flour and preparations

Frequently Asked Questions

How many trademarks does Inner Mongolia Keran Bio-Tech Co., Ltd have?

Inner Mongolia Keran Bio-Tech Co., Ltd has 3 U.S. trademarks filed with the USPTO.

What trademark classes does Inner Mongolia Keran Bio-Tech Co., Ltd file in?

Inner Mongolia Keran Bio-Tech Co., Ltd files trademarks across 3 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 5 (Pharmaceuticals), Class 30 (Staple Foods). Class 35 covers advertising; business management; business administration; office functions.

What is Inner Mongolia Keran Bio-Tech Co., Ltd's trademark registration success rate?

Inner Mongolia Keran Bio-Tech Co., Ltd has a 0% trademark registration rate, with 0 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.